Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Prepaid Assets (2016 - 2025)

Adma Biologics (ADMA) has disclosed Prepaid Assets for 14 consecutive years, with $7.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Prepaid Assets fell 7.11% year-over-year to $7.5 million, compared with a TTM value of $7.5 million through Dec 2025, down 7.11%, and an annual FY2025 reading of $7.5 million, down 7.11% over the prior year.
  • Prepaid Assets was $7.5 million for Q4 2025 at Adma Biologics, up from $6.9 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $9.5 million in Q3 2024 and bottomed at $3.7 million in Q1 2024.
  • Average Prepaid Assets over 5 years is $6.1 million, with a median of $5.5 million recorded in 2022.
  • Peak annual rise in Prepaid Assets hit 129.59% in 2025, while the deepest fall reached 27.4% in 2025.
  • Year by year, Prepaid Assets stood at $4.3 million in 2021, then rose by 17.42% to $5.1 million in 2022, then grew by 4.69% to $5.3 million in 2023, then surged by 50.52% to $8.0 million in 2024, then fell by 7.11% to $7.5 million in 2025.
  • Business Quant data shows Prepaid Assets for ADMA at $7.5 million in Q4 2025, $6.9 million in Q3 2025, and $8.1 million in Q2 2025.